Coherus Oncology (CHRS) Total Debt Growth (3y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 6.94% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 50.25% |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 0.07% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Coherus Oncology | 216.87 Mn | 49.83 Mn | 8.50 Mn | -46.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -46.74% |
| Dec 31, 2025 | -46.76% |
| Sep 30, 2025 | -46.79% |
| Jun 30, 2025 | -42.71% |
| Mar 31, 2025 | -31.48% |
| Dec 31, 2024 | -12.66% |
| Sep 30, 2024 | -15.23% |
| Jun 30, 2024 | -15.18% |
| Mar 31, 2024 | -1.01% |
| Dec 31, 2023 | 49.68% |
| Sep 30, 2023 | 111.34% |
| Jun 30, 2023 | 49.22% |
| Mar 31, 2023 | 110.69% |
| Dec 31, 2022 | 49.37% |
| Sep 30, 2022 | 111.09% |
| Jun 30, 2022 | 96.16% |
| Mar 31, 2022 | 96.35% |
| Sep 30, 2021 | 43.09% |
| Jun 30, 2021 | 43.09% |
| Mar 31, 2021 | 43.10% |
| Dec 31, 2020 | 42.18% |
| Sep 30, 2020 | -0.38% |
| Jun 30, 2020 | 40.80% |
| Mar 31, 2020 | -0.86% |
| Dec 31, 2019 | 37.07% |
| Sep 30, 2019 | -4.54% |
| Jun 30, 2019 | -6.03% |
| Mar 31, 2019 | -5.94% |
| Sep 30, 2018 | 56.66% |
| Dec 31, 2017 | 105.24% |
| Sep 30, 2017 | 98.46% |